Background: Differentiating depression in major depressive disorder and bipolar disorder is challenging in clinical practice. Therefore, reliable biomarkers are urgently needed to differentiate between these diseases. This study's main objective was to assess whether cardiac autonomic function can distinguish patients with unipolar depression (UD), bipolar depression (BD), and bipolar mania (BM).
Methods: We recruited 791 patients with mood disorders, including 191 with UD, 286 with BD, and 314 with BM, who had been drug free for at least 2 weeks. Cardiovascular status was measured using heart rate variability (HRV) and pulse wave velocity (PWV) indicators via finger photoplethysmography during a 5-min rest period.
Results: Patients with BD showed lower HRV but higher heart rates than those with UD and BM. The PWV indicators were lower in the UD group than in the bipolar disorder group. The covariates of age, sex, and body mass index affected the cardiovascular characteristics. After adjusting for covariates, the HRV and PWV variations among the three groups remained significant. Comparisons between the UD and BD groups showed that the variable with the largest effect size was the frequency-domain indices of HRV, very low and high frequency, followed by heart rate. The area under the receiver operating characteristic curve (AUC) for each cardiovascular variable ranged from 0.661 to 0.714. The High-frequency index reached the highest AUC.
Limitations: Cross-sectional design and the magnitude of heterogeneity across participants with mood disorders limited our findings.
Conclusion: Patients with BD, but not BM, had a greater extent of cardiac imbalance than those with UD. Thus, HRV may serve as a psychophysiological biomarker for the differential diagnosis of UD and BD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jad.2023.08.128 | DOI Listing |
Cannabis
December 2024
Institute for Mental Health and Policy Research, Centre for Addiction and Mental Health.
Objective: Since the federal Canadian government legalized cannabis in 2018, cannabis use in the general population has slightly increased. However, little is known about the impact of cannabis legalization on pattens of cannabis use in psychiatric populations.
Method: We studied changes in daily/almost daily and average 30-day cannabis use amongst individuals currently using cannabis who reported past 12-month experiences of specific mental health disorders and among those without past 12-month experiences of any mental health disorder before and after Canadian legalization of recreational cannabis use ( = 13,527).
Cureus
December 2024
Internal Medicine, Saint Joseph Hospital-Intermountain Health, Denver, USA.
The pupillary reflex is a complex physiological response involving both the eye and associated neural pathways. Relative afferent pupillary defects (RAPDs) can present due to various underlying pathologies, yet their occurrence in serotonin syndrome has been rarely documented. This report details the case of a 21-year-old non-binary individual with a history of bipolar disorder who presented to the emergency department following a polypharmacy overdose, including significant ingestion of sertraline, aripiprazole, and buspirone.
View Article and Find Full Text PDFSci Data
January 2025
University of Bergen, Department of Clinical Medicine, Bergen, 5009, Norway.
Mental health is vital to human well-being, and prevention strategies to address mental illness have a significant impact on the burden of disease and quality of life. With the recent developments in body-worn sensors, it is now possible to continuously collect data that can be used to gain insights into mental health states. This has the potential to optimize psychiatric assessment, thereby improving patient experiences and quality of life.
View Article and Find Full Text PDFSchizophr Bull
January 2025
Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX 75390, United States.
Background: Investigations of causal pathways for psychosis can be guided by the identification of environmental risk factors. A recently developed composite risk tool, the exposome score for schizophrenia (ES-SCZ), which controls for intercorrelations between risk factors, has shown fair to good performance. We tested the transdiagnostic psychosis classifier performance of the ES-SCZ with the Bipolar-Schizophrenia Network for Intermedial Phenotypes data and examined its relationship with clinical-level outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!